Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Peng-Peng Xu, Yue Zhu, Zi-Yang Shi, Li Wang, Shu Cheng, Ying Qian, Yan Zhao, Yang He, Hong-Mei Yi, Bin-shen Ou-yang, Xu-Feng Jiang, Biao Li, Qi Song, Rong-Ji Mu, Wei-Li Zhao

Blood (2025) 146 (21): 2561–2573.

https://doi.org/10.1182/blood.2025028649

Published: 2025

Includes: Supplemental data

Journal Articles

Enhanced IPSS-m: A comorbidity-integrated model for improved clinical risk stratification in myelodysplastic neoplasms

Vikramjit Dhillon, Jeff Justin Aguilar, Sikander Chohan, Anisha Rajavel, Nagasai Yalavarthi, Dakshin Padmanabhan, Sushmitha Nanja Reddy, Yang Shi, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 3871.

https://doi.org/10.1182/blood-2025-3871

Published: 2025

Journal Articles

Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia

Jeff Justin Aguilar, Vikramjit Dhillon, Sikander Chohan, Dakshin Padmanabhan, Sushmitha Nanja Reddy, Asmita Shukla, Nagasai Yalavarthi, Anisha Rajavel, Sonubar Virk, Breanna Williams, Julie Boerner, Yang Shi, Jay Yang, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2025-3496

Published: 2025

Journal Articles

Targeting the compass complex to overcome resistance in KMT2A-rearranged Acute Myeloid Leukemia

Sandhya Dhiman, Vikramjit Dhillon, Jeff Justin Aguilar, Julie Boerner, Yang Shi, Jay Yang, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2025-1517

Published: 2025

Journal Articles

Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)

Jessica Li, Yang Shi, Linlin Xu, Xiaopeng Ma, Marcus Lefebure, Tommi Salmi, Teiko Sumiyoshi, Inhye Ahn

Blood (2025) 146 (Supplement 1): 5681.

https://doi.org/10.1182/blood-2025-5681

Published: 2025

Journal Articles

Clinical implications of epigenetic age acceleration as a novel biomarker in Acute Myeloid Leukemia

Vikramjit Dhillon, Jeff Justin Aguilar, Valeria Visconte, Zachary Brady, Julie Boerner, Yang Shi, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 5290.

https://doi.org/10.1182/blood-2025-5290

Published: 2025

Journal Articles

A prospective, multicenter, randomized, controlled clinical trial comparing polatuzumab vedotin, zanubrutinib, lenalidomide, and rituximab (Pola-ZR2) versus zanubrutinib, lenalidomide, and rituximab (ZR2) in the treatment of previously untreated, elderly patients with diffuse large B-cell lymphoma (NCT06522555)

Fan Zhang, Zi-Yang Shi, Qing Shi, Yan Zhu, Wei Li Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 3696.

https://doi.org/10.1182/blood-2025-3696

Published: 2025

Journal Articles

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Blood (2024) 144 (22): 2360–2363.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Age and Race on Survival in Adult T-Cell Leukemia/Lymphoma in the United States

Madeline G D'Agostino, B. Hilda Ye, Murali Janakiram, Dennis L Cooper, Ioannis Mantzaris, Aditi Shastri, Mendel Goldfinger, Noah Kornblum, Nishi Shah, Amit Verma, Lauren Shapiro, Ridhi Gupta, Yang Shi, Yanhua Wang, Alyssa De Castro, John X Wei, R. Alejandro Sica

Blood (2024) 144 (Supplement 1): 7732.

https://doi.org/10.1182/blood-2024-208561

Published: 2024

Journal Articles

Post-Transplantation Cyclophosphamide and Abatacept Graft-Versus-Host-Disease Prophylaxis Shows Improved Outcomes in North American Adult T-Cell Leukemia/Lymphoma

Blood (2024) 144 (Supplement 1): 7367.

https://doi.org/10.1182/blood-2024-207521

Published: 2024

Journal Articles

Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Blood (2024) 144 (Supplement 1): 3067.

https://doi.org/10.1182/blood-2024-208199

Published: 2024

Journal Articles

Discovery of the Unique GMP-Grade iPSC Clones That Give Rise to Functional, High Purity, Matured CD8 Alpha Beta T or Gamma Delta T with Exponential Expansion Capacity

Blood (2024) 144 (Supplement 1): 7195.

https://doi.org/10.1182/blood-2024-203106

Published: 2024

Journal Articles

Targeting Intracellular Mutant NPM1 in Acute Myeloid Leukemia with a Novel Peptide-MHC-Specific T-Cell Bispecific Antibody

Yunda Hong, Dabing Chen, Jingjing Xu, Yanxin Chen, Yangtao Wu, Yang Shi, Tianying Zhang, Quan Yuan, Ningshao Xia, Ting Yang, Jianda Hu

Blood (2024) 144 (Supplement 1): 2210.

https://doi.org/10.1182/blood-2024-209636

Published: 2024

Journal Articles

Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study

Jennifer R. Brown, Jessica Li, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Luqui Qiu, Vanitha Ramakrishnan, Ruiqi Huang, Yang Shi, Adam Idoine, Tommi Salmi, Aileen Cleary Cohen, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 1890.

https://doi.org/10.1182/blood-2023-173547

Published: 2023

Journal Articles

Evaluation of CNS Involvement in Secondary AML: Incidence and Impact on Outcome

Blood (2022) 140 (Supplement 1): 11653–11655.

https://doi.org/10.1182/blood-2022-158112

Published: 2022

Journal Articles

Outcomes Analysis of T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL) in a Minority Rich Cohort

Blood (2022) 140 (Supplement 1): 11595–11597.

https://doi.org/10.1182/blood-2022-159826

Published: 2022

Journal Articles

Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

Blood (2022) 140 (Supplement 1): 662–664.

https://doi.org/10.1182/blood-2022-170332

Published: 2022

Journal Articles

Pre-Conditioning Easix Is Associated with Survival after Autologous Hematopoietic Stem Cell Transplant in Mature T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 12928–12929.

https://doi.org/10.1182/blood-2022-170810

Published: 2022

Journal Articles

Outcomes of Autologous Stem Cell Transplantation for Relapsed DLBCL in Single Center Serving a Minority Population

Blood (2022) 140 (Supplement 1): 13225–13227.

https://doi.org/10.1182/blood-2022-170633

Published: 2022

Journal Articles

Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia

Jiani Chai, Jui Choudhuri, Qing Wang, Yanan Fang, Yang Shi, Wa Shen, Swati Goel, Ioannis Mantzaris, Aditi Shastri, R. Alejandro Sica, Nishi Shah, Kira Gritsman, Marina Konopleva, Noah Kornblum, Amit Verma, Mendel Goldfinger, Yanhua Wang, Xuejun Tian

Blood (2022) 140 (Supplement 1): 6256–6257.

https://doi.org/10.1182/blood-2022-162857

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Enhanced IPSS-m: A comorbidity-integrated model for improved clinical risk stratification in myelodysplastic neoplasms

Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia

Targeting the compass complex to overcome resistance in KMT2A-rearranged Acute Myeloid Leukemia

Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)

Clinical implications of epigenetic age acceleration as a novel biomarker in Acute Myeloid Leukemia

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Impact of Age and Race on Survival in Adult T-Cell Leukemia/Lymphoma in the United States

Post-Transplantation Cyclophosphamide and Abatacept Graft-Versus-Host-Disease Prophylaxis Shows Improved Outcomes in North American Adult T-Cell Leukemia/Lymphoma

Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Discovery of the Unique GMP-Grade iPSC Clones That Give Rise to Functional, High Purity, Matured CD8 Alpha Beta T or Gamma Delta T with Exponential Expansion Capacity

Targeting Intracellular Mutant NPM1 in Acute Myeloid Leukemia with a Novel Peptide-MHC-Specific T-Cell Bispecific Antibody

Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study

Evaluation of CNS Involvement in Secondary AML: Incidence and Impact on Outcome

Outcomes Analysis of T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL) in a Minority Rich Cohort

Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

Pre-Conditioning Easix Is Associated with Survival after Autologous Hematopoietic Stem Cell Transplant in Mature T-Cell Lymphomas

Outcomes of Autologous Stem Cell Transplantation for Relapsed DLBCL in Single Center Serving a Minority Population

Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only